Pharmaceuticals, Biotechnology & Life Sciences

QIAgen’s new data shows QuantiFERON‑TB Gold Plus detects TB faster and cheaper than TST, cutting costs by ~$1,200 per patient and boosting accuracy above 95 %.

Waters Corporation’s 2026 senior notes offering via Augusta SpinCo boosts long‑term growth funding, offering tiered maturities, rising rates, and strong credit guarantees.

Newron Pharmaceuticals reveals Evenamide’s breakthrough glutamate‑modulating data ahead of SIRS 2026, positioning a first‑in‑class therapy for treatment‑resistant schizophrenia, with strategic pricing, patent, and partnership plans that could drive …

German TecDAX faces a downturn, yet cloud and enterprise software firms like IONOS and SAP thrive, while Sartorius AG projects high‑single‑digit growth in bioprocessing by 2027.

Insightful analysis of Natera’s insider trades shows routine Rule 144/10b‑5‑1 filings, minimal financial impact, and strong governance signals for investors.

Argenx’s regulatory setbacks in Europe could slash projected revenue by 41% and erode NPV. Discover how data‑package expansion, outcome‑based pricing, and targeted M&A may salvage growth.

Royalty Pharma plc’s former officers will sell 100,462 shares under a pre‑approved selling plan, with Goldman Sachs handling the compliant Rule 144 transaction.

CSL’s inclusion in the State Street SPDR S&P /ASX 50 ETF marks it as a top‑50 Aussie stock, yet the real value lies in its biosimilar pipeline and adaptive clinical trials that keep investors focused on future growth rather than today’s price tag.

March 18 2026 S&P 500 drops 1.5%—a careful look at sector swings, high dividend yields, and tightening rates shows why investors stay defensive yet seek tech‑driven upside.

AbbVie’s role in tech‑focused index funds remains steady amid market volatility, showing how the pharma firm balances growth and risk for investors.